STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive

STAT PlusPharmalot Supreme Court justices appear to signal ‘skinny labeling’ can survive The case generated concerns that a key path for generics may be closed off Manage alerts for this article Email this article Share this article By Ed SilvermanApril 29, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. After months of anticipation, Supreme Court justices heard arguments about a long-standing tactic used by generic companies to carve out a distinct market for a medicine, and did not appear inclined to alter legal standards for the maneuver. At issue is skinny labeling, which refers to moves by generic companies that seek regulatory approval to market a drug for a specific use, but not other patented uses for which a brand-name medicine is prescribed. For instance, a generic drug could be marketed to treat one type of heart problem but not another. In doing so, the generic company seeks to avoid lawsuits claiming patent infringement.Advertisement This tactic has been a key tool for generic companies ever since the Hatch-Waxman Act was signed into law more than four decades ago. The law established the mechanisms by which generic drugs can more readily enter the marketplace. And skinny labeling is one way that Congress attempted to foster more competition and benefit consumers. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In patents, Pharmaceuticals, Policy, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. STAT+ Newsletter Pharmalot columnist Ed Silverman rounds up the most important news of the day in the global drug industry Recommended Pharmalot April 29, 2026 STAT Plus: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more Pharmalot April 28, 2026 STAT Plus: AIDS group sues Trump administration over undisclosed agreement with Gilead Advertisement Pharmalot April 28, 2026 STAT Plus: Supreme Court to hear case about ‘skinny labeling’ and generic access Pharmalot April 28, 2026 STAT Plus: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more Pharmalot April 27, 2026 STAT Plus: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more Subscriber Picks